- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02437344
Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence
Opioid dependence is a substantial problem associated with significant morbidity and mortality. Extended-release naltrexone has been found effective at reducing opioid use and maintaining abstinence, but its use has been limited by the difficulties encountered with treatment initiation, which involves detoxification from opioids and oral naltrexone titration. Improving the likelihood of a successful transition to naltrexone is therefore an important public health goal.
N-methyl-D-aspartate receptor (NMDA) antagonism has been found to alleviate the signs and symptoms of withdrawal from opioids, as well as to address adaptations associated with chronic opioid use, such as opioid-induced hyperalgesia (increased pain sensitivity). These benefits may persist for at least 72 hours after a single dose. NMDA antagonism may therefore facilitate a rapid transition to naltrexone by reducing discomfort, improving motivation, and ameliorating adaptations associated with drug dependence, such as craving and arousal.
The purpose of this trial is to assess the feasibility of NMDA antagonist-assisted naltrexone initiation in opioid dependent individuals. After administration of extended-release naltrexone, participants will be followed for 4 weeks, and transitioned to appropriate care subsequently (oral naltrexone, extended-release naltrexone).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- New York State Psychiatric Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Active opioid dependence, with at least one positive utox result; no history of opioid overdose; and not currently using methadone or buprenorphine
- Physically healthy
- No adverse reactions to study medications
- 21-60 years of age
- Capacity to consent and comply with study procedures
- Seeking treatment
Exclusion Criteria:
- Meets DSM IV criteria for current major depression, bipolar disorder, schizophrenia, any psychotic illness, including substance-induced psychosis, and current substance-induced mood disorder with HAMD > 12.
- Physiological dependence on another substance requiring medical management, such as alcohol or benzodiazepines, excluding caffeine, nicotine, and cannabis
- Pregnant or interested in becoming pregnant
- Delirium, Dementia, Amnesia, Cognitive Disorders, or dissociative disorders
- Current suicide risk or a history of suicide attempt within the past 2 years
- On psychotropic or other medication whose effect could be disrupted by participation in the study
- Recent history of significant violence (past 2 years).
- Heart disease as indicated by history, abnormal ECG, previous cardiac surgery.
- Unstable physical disorders which might make participation hazardous such as end-stage AIDS, hypertension (>140/90), anemia, active hepatitis or other liver disease (transaminase levels < 2 X the upper limit of normal will be considered acceptable), or untreated diabetes
- Previous history of CI-581 abuse, and/or a history of adverse reaction/experience wtih prior exposure to CI-581 or benzodiazepines
- BMI > 35, or a history of unmanaged obstructive sleep apnea
- First degree relative with a psychotic disorder (bipolar disorder with psychotic features, schizophrenia, schizoaffective disorder, or psychosis NOS)
- History of opioid overdose over the past 2 years requiring medical intervention
- Currently using methadone or buprenorphine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CI-581aa
CI-581aa will be administered 24 hours after last opioid use, and followed by naltrexone dosing
|
92 minute infusion of CI-581aa
Other Names:
participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Successful Naltrexone Initiation
Time Frame: 2 weeks
|
The proportion of participants enrolled in the trial and receiving the infusion to receive XR-NTX
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Withdrawal: Subjective Opioid Withdrawal Scale (SOWS) Scores at Baseline and Administered Subsequently
Time Frame: 4 days
|
Subjective Opioid Withdrawal Scale (SOWS) is a scale out of 64 points assessing withdrawal severity that is administered serially, every several hours, over the course of the naltrexone initiation.
The questionnaire assesses symptoms that the patient rates on a scale of 0 (not at all) to 4 (extremely).
The difference in total (sum) scores between baseline and end-of-induction will be reported.
Scores range from 0 to 64.
|
4 days
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- #7057
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Dependence
-
National Development and Research Institutes, Inc.Unknown
-
Milton S. Hershey Medical CenterRecruitingOpioid Dependence FentanylUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)Completed
-
MindLight, LLCMclean HospitalRecruitingOpioid Dependence | Opioid Use | Opioid Abuse | Opiate Dependence | Opioid Use, Unspecified | Opioid Use Disorder, ModerateUnited States
-
Orexo ABWorldwide Clinical TrialsCompletedOpioid Dependence, on Agonist TherapyUnited States
-
National Development and Research Institutes, Inc.St. Luke's-Roosevelt Hospital CenterUnknownOpioid-Dependence Among AdolescentsUnited States
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA)CompletedOpioid Dependence | Opioid-use Disorder | Opiate DependenceUnited States
-
Indivior Inc.CompletedOpioid Dependence | Cocaine Dependence | Opioid Related DisordersUnited States
-
Orexo ABWorldwide Clinical TrialsCompletedOpioid Dependence, on Agonist TherapyUnited States
-
NYU Langone HealthNational Institute on Drug Abuse (NIDA)Completed
Clinical Trials on CI-581aa
-
Universitair Ziekenhuis BrusselRecruitingSensorineural Hearing Loss | Cochlear ImplantsBelgium
-
HealthPartners InstituteNational Institute on Aging (NIA); OCHIN, Inc.RecruitingCognitive Impairment | DementiaUnited States
-
University of MiamiCochlearCompleted
-
Matthew Bush, MDCompletedHearing Loss | Hearing DisordersUnited States
-
Ohio State UniversityActive, not recruitingStroke | HemiparesisUnited States
-
Ohio State UniversityUniversity of Missouri-Columbia; University of Alabama at Birmingham; University... and other collaboratorsCompletedEffectiveness of Virtual Reality Gaming Therapy Versus CI Therapy for Upper Extremity RehabilitationStroke | HemiparesisUnited States
-
MED-EL Elektromedizinische Geräte GesmbHRecruiting
-
George Papanicolaou HospitalNot yet recruitingCoronary Artery Disease | Aortic Valve Disease | Mitral Valve Disease
-
University of Massachusetts, LowellOhio State UniversityCompletedHemiparesis | Primary Progressive Multiple SclerosisUnited States
-
Advanced Bionics AGNot yet recruitingHearing Loss, Sensorineural | Severe-to-profound Hearing LossBelgium, United Kingdom, France, Germany, Italy, Poland